title: Low-FODMAP Diet for Irritable Bowel Syndrome: Is It Ready for Prime Time?
abstract: Irritable bowel syndrome (IBS) is a chronic gastrointestinal disease, which adversely affects the quality of life. Its prevalence has been reported to be around 10-15 % in North America and constitutes the most common cause for gastroenterology referral. Unfortunately, the pathophysiology of IBS is not completely understood. Not surprisingly, the management strategies can leave the patients with inadequate symptom control, making IBS a debilitating gastrointestinal syndrome. Dietary interventions as a treatment strategy for IBS have been recently evaluated. One such intervention includes dietary restriction of fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs). FODMAPs define a group of short-chain carbohydrates that are incompletely absorbed in small intestine and later fermented in the colon. Evidence in the form of randomized controlled trials and observational studies have evaluated the mechanism of action and efficacy of low-FODMAP diet. This dietary intervention has showed promising results in symptom reduction in IBS patients. However, latest trials have also shown that the low-FODMAP diet is associated with marked changes in gut microbiota specifically reduction in microbiota with prebiotic properties. Implications of such changes on gastrointestinal health need to be further evaluated in future trials.
authors.affiliation: Department of Gastroenterology, University of Toledo, Toledo, OH, USA.
authors.forename: Muhammad Ali
authors.initials: MA
authors.lastname: Khan
authors.forename: Salman
authors.initials: S
authors.lastname: Nusrat
authors.forename: Muhammad Imran
authors.initials: MI
authors.lastname: Khan
authors.forename: Ali
authors.initials: A
authors.lastname: Nawras
authors.forename: Klaus
authors.initials: K
authors.lastname: Bielefeldt
mesh_terms: D050528:Diet, Carbohydrate-Restricted; D004040:Dietary Carbohydrates / Q000008:administration & dosage* / Q000378:metabolism; D005285:Fermentation; D006801:Humans; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000378:metabolism*; D007422:Intestines / Q000382:microbiology; D043183:Irritable Bowel Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D004040:Dietary Carbohydrates